URB597
URB597 is a relatively selective inhibitor of the enzyme fatty acid amide hydrolase. FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. URB597 has been found to elevate anandamide levels and have activity against neuropathic pain in a mouse model.
URB597 was at one point being developed by Kadmus Pharmaceuticals, Inc. for clinical trials in humans.
